Discovery Life Sciences and Mindpeak Team Up to Enhance Cancer Biomarker Testing with AI Precision

AI-Powered Precision in Cancer Biomarker Testing

Introduction

The interpretation of cancer biomarkers is a critical yet challenging aspect of clinical trials. Inconsistent assessments among pathologists can lead to variability in patient stratification and undermine confidence in vital decision-making processes. To address this pressing issue, Discovery Life Sciences and Mindpeak have announced a strategic partnership to incorporate digital imaging analysis powered by artificial intelligence (AI) into immunohistochemistry (IHC) and multiplex immunofluorescence (mIF) testing for global clinical trials.

The Problem of Inconsistent Interpretation

The inconsistency in biomarker interpretation by pathologists has been recognized as one of the most persistent challenges in drug development. This variability can affect how patients are stratified in clinical trials, complicating the process for clinicians and researchers. Both companies have joined forces to provide improved solutions focusing on quantitative biomarker assessment and enhancing consistency between readers, thereby reducing variability and minimizing the risks associated with biomarker-based studies.

Partnership Overview

This innovative collaboration blends Mindpeak’s AI capabilities with Discovery's extensive biomarker services, specifically in analyzing IHC and mIF slides. By integrating AI-driven tools, they aim to enhance the accuracy of biomarker interpretation, acting as a safeguard for biopharmaceuticals. The partnership includes support for pathologists through AI-enhanced workflows, educational training via Mindpeak's peakAcademy, and micro-dissecting algorithms to precisely isolate tissue areas.

Discovery Life Sciences brings to the table a robust clinical infrastructure, highlighted by its Biomarker Academy, which has trained over 6,000 pathologists in biomarker interpretation over the past 15 years. With experience supporting over 2,000 clinical research programs, including 350 currently active studies, this collaboration aims to extend the achievements of Discovery in AI, leveraging current AI solutions focused on histopathology to ensure high-quality analysis of biomarker specimens.

Enhancing Drug Development Through AI

Greg Herrema, CEO of Discovery Life Sciences, stated, "As the use of AI in pathology grows for clinical research, this partnership with Mindpeak allows us to integrate modeling tools that can increase the accuracy of biomarker analyses. Combining these AI capabilities with our clinical trial expertise will advance the development of biomarker-driven therapies.” This partnership is expected to streamline trial processes and enhance data reproducibility in regulated environments, supporting more confident patient stratification and therapeutic development.

Felix Faber, founder and CEO of Mindpeak, added, “This collaboration with Discovery Life Sciences provides access to our AI platform, educational tools, and micro-dissecting capabilities, aiding researchers in IHC and mIF while improving consistency and confidence in biomarker evaluations.”

Future Perspectives

Additional information regarding the partnership and its applications will be presented at the AACR Annual Meeting 2026, where attendees are invited to take part in a flash talk at the Discovery Life Sciences booth from April 17 to 22 at the San Diego Convention Center. For specific inquiries, you may contact [email protected]

Conclusion

As the landscape of cancer research evolves, partnerships like that of Discovery Life Sciences and Mindpeak signal a powerful shift towards data-driven solutions that enhance the precision of medical research. By addressing the inherent challenges in biomarker testing, these companies are paving the way for more reliable patient outcomes and advancing the future of healthcare.

Company Backgrounds

Discovery Life Sciences

Discovery Life Sciences stands out as a global leader in bioproducts and specialized laboratory services, committed to uncovering and developing therapeutic and diagnostic solutions aimed at improving patient outcomes. Their extensive portfolio of biomarker and preclinical solutions accelerates research with dependable, high-quality products and expertise.

Mindpeak

Founded in 2018, Mindpeak specializes in digital pathology powered by artificial intelligence, bridging the gap between biomarker development and clinical diagnostics. Their AI technology enables laboratories to extract valuable insights from tissue images, resulting in improved patient stratification and the implementation of new clinical applications.

For more information about Discovery Life Sciences, visit www.dls.com and follow them on LinkedIn. To learn about Mindpeak, visit www.mindpeak.ai and follow their LinkedIn page.